Businesses for Sale and Investment Opportunities in San Pedro Sula

- We are a construction company based in Honduras and have served more than 150 clients. - We have completed 30 residential projects since 2016. Also, we have worked on remodel offices, built warehouses and offices. All together have completed 150 projects. - We have 5 other projects in the pipeline. - Seeking funds to purchase land and build our own office.

- One of the world’s largest and most intensive Tilapia projects, designed by APT (Aquaculture Production Technology) 25 years ago. - Awarded the gold medal for taste and freshness of our fish 15 years back by the American Tasting Institute. - The company has been inactive for many years and needs an investor to reactivate the operations. - Company would operate in a free zone, which guarantees the tranquillity in its work. - The facility has the minimum production capacity of approximately 15,000 tons of fillet per season. - Water source: Discharge from a hydroelectric power plant, Lake Yojoa. - Company used to sell USD 80 million worth of products annually to a buyer in the US in the past and the same buyer is ready to purchase products from the company once the operations are restarted. - Advisor who listed the business is based in the US, as a result, using the local number.

- Cigar manufacturer with a complete retail supply chain. - Offers a diverse range of 13 cigar lines with licensing agreements for various markets. - Maintains full control over production and distribution processes globally, supported by licenses and permits. - Brand protected by trademark. - Company has its own tobacco farm. - Impressive cultivation capacity of 300,000 cigars per month, currently operating at 10,000. - Seven years of industry experience. - Holds business registrations and sanitary licenses in Honduras and the United States. - Distribution network includes one distributor each in the US, Colombia, and Canada apart from Honduras. - Engages in both business-to-consumer (B2C) and business-to-business (B2B) transactions. - Utilizes contract workers for employment.

The Magnat company works in the field of pre-sale and pre-lease preparation of real estate. Our business model consists precisely of the rapid pre-sale preparation of real estate for sale or rent. We spend 1-3 days to fully cosmetically prepare the property for sale. Our services include cleaning (general cleaning), window washing, garbage removal, small electrical and plumbing work, small tiling work, small painting or wallpaper work, dismantling of old equipment and furniture, small cosmetic decorations (plinths, curtains, baguettes, etc. ), professional photo-video. At the exit, our client receives a wonderful real estate object ready to be put up for sale. Our services increase the value of such real estate, and increase the number of people willing to buy it, as a result, the speed of sale increases by 3-10 times, and the cost by 10-20%. Many realtors cooperate with us because they are eager to cooperate with us and give us orders as well. We have a lot of clients, as our services are popular, they are 5-10 times cheaper than repairs, and faster, and this is exactly what people who want to quickly sell their real estate need - a low cost and a quick result. This is the key to our business model. The current partners are generating the mentioned revenue with the investment amount mentioned.

We have won numerous awards for best residential developments in Central America from the International Property Awards. We have sold to over 200 clients. We are in the 5th phase of the two projects having a beautiful property with more land to develop on.

- UK's biggest exporter of plant-based skincare and supplements. - New stem cell innovation for cancer scars. - Fastest growing sector of skin care. - We are a group of scientists and plastic surgeons formulating according to the latest medical research. - We have recently launched our new product which is stem cell innovation for cancer scars. - Business won't be charging any brand fees or royalties as our main focus is to grow globally. - Monthly sales will depend upon our distributor partner and how much he/she is able to sell. - The franchise formats mentioned are estimated figures based on the already existing revenue of the business. - We request you to visit our website and check the awards our product has received.

- Family business grew since last 8 years at 145% in sales to retake the national market. - The business manufactures and sells ice cream. - We are serving 90 stores nationally and 2,500 private sellers. - Highly nostalgic brand plus quality, we can overtake regional competitors and penetrate regional markets. - Ice cream market is valued at USD 75 million.

- Commercial property of 5,000 sq ft in Honduras with all facilities. - It has 10 rooms, parking space, very close to restaurants and laundry shop. - Can be converted into hotel, hostel or resort. - Large underground water storage facilities and sufficient overhead water storage facilities. - Property has a good potential but building needs repairing.

- Our company is into manufacturing of plastic containers, lids and screen printing. - Have over 150 customers out of which approximately 50 customers are permanently re-stocking their inventories with us. - Our customers are mainly in Honduras and neighboring countries of Central America, including Panama. - Have over 28 years of experience in the field of manufacturing plastic packaging containers and lids. - Our company is ISO 9001-2008 certified.

Number of Clients: 100 active wholesalers and we serve a wide range of clients, including the general public of all ages, businesses requiring sugar for their products, companies looking for promotional candies, and manufacturers using candies in toys and other products. Revenue Model: Revenue is generated primarily from the sale of candies and sweets. This includes direct sales to consumers and B2B sales to other businesses for promotional purposes or as ingredients. The company plans to expand its revenue streams by entering new distribution channels, such as online sales, supermarkets, convenience stores, departmental stores, clubs, and international markets. Promoter Experience: The company has a rich history dating back to its founding in 1902. The current leadership brings extensive experience in the confectionery industry. The company's executive team is noted for its skills in strategic planning, operational management, and market expansion. Business Relationships: The company has developed strong relationships with a diverse range of clients and suppliers. This includes major retailers, wholesalers, and promotional clients. The company's strategy involves fostering relationships with distributors and commission agents, forming an integral part of their value chain. Awards and Recognitions: the company's long-standing presence in the market and brand strength suggest a positive reputation in the industry. Additional Highlights: Market segmentation is diverse, targeting wholesale, retail, club stores, convenience stores, and department stores. The company emphasizes product quality, innovation, and customer satisfaction in its operational strategy. The company is actively involved in community welfare programs and is committed to environmentally sustainable practices.

- R+D and distribution of vegetable seeds. - Exclusivity of highest yielding Roma tomato variety that will change the 12,000 hectares market in Mexico for the next 4-8 years with a potential revenue of US$20-30M per year only for this variety alone. - Great network of suppliers and clients. - There are 20 permanent employees. No additional contract/temporary employees.

- We are a start-up hospitality company seeking equity investment/funding of US$27 million from one or more investors for up to 18% of our company. - The minimum we will accept from a single investor is US$600,000 at a rate of US$3.00 per share. Investments of US$9 million and over will be at a rate of US$1.50 per share. - After receiving start-up funding, we will be seeking business loans of almost US$950 million in 8 phases for the acquisition and renovation of several turnkey and non-operational hotels, resorts, and villas as well as the acquisition of development lands and the construction of permanent corporate headquarters, first luxury hotel & resort, and a couple of large-scale farms. - Individual investors will get FREE all-Inclusive stays for up to 2 years at any of our future hotels & resorts of their choice. All Investors and shareholders will be paid dividends monthly from revenues or net profits according to their percentage of ownership in the company. Dividends will be increased yearly as revenues increase. - Investors will be issued a digital copy of their shares/stock certificate which will be available for download from the online equity and shares management service at Eqvista. Investors will be registered as shareholders within 30 days at the local company registrar in Jamaica. - Start-up capital will be used as working capital for fundraising, professional fees, and expenses for auditing, legal, operating, travel, security, marketing, market research, business planning, feasibility studies, architectural designing, and master planning. - Our hotels & resorts will provide a wide variety of products, services, amenities, and activities to our guests. The hotels will also have many unique features as well as present and future state-of-the-art technologies that will set them apart from our competitors. - We plan to build and operate numerous hotels and resorts for a number of specialized purposes including for business, sports, families, adults, nature/eco-tourism, agri-tourism, and health/wellness/medical tourism. - We also intend to provide our guests with food grown from our own farms; shuttle services to and from airports and our resorts; planning and hosting events such as weddings and birthday parties; providing entertainment such as concerts and stage shows; providing tours and excursions to popular tourist attractions; and travel services using a fleet of cars, buses, vans, coaches, yachts and aircraft. - Once we have startup capital, we will be able to attract larger investments in order to purchase existing turnkey hotels and resorts and begin earning revenue from them immediately. - Owner/Promoter is a Jamaican citizen and has 10 years of experience working in the financial industry as an Accounting Officer at a well-established loans company in Kingston, Jamaica. - The pictures attached are a representation of our main products and services, the logo of our company and the office space or building we would like to rent. - When you connect with us you will have access to our Executive Summary, Business Plan, Pitch Deck, Financial Projections and a brochure containing descriptions of real estate such as hotels, resorts, villas, lands and office space we would like to purchase in Jamaica.

- The company currently works with pharmaceutical and diagnostic companies, research institutes, CROs, and CDMOs to help them develop molecular bioassays and digital pathology products, and to visualize and analyze the resultant data via AI and ML for the benefit of patients, their family, and their healthcare providers. - Currently, has 3 clients: Klotho Therapeutics Inc. (a biotechnology company in San Diego, CA, USA), Unger Medical PC (a hair restoration medical practice in NY, NY, USA), and Astrix Technology Group (a life sciences strategy, technology, and staffing services company based in Red Bank, NJ, USA). • Target Market: - The business is specialized in developing diagnostics and therapeutics for human basal cell carcinoma, squamous cell carcinoma, and melanoma. This skin cancer group comprises the most diagnosed cancers worldwide of all cancer types with over five million cases diagnosed each year. - The skin cancer therapeutics diagnostics and therapeutics products industry worldwide were worth $8.2 billion USD in 2019 and is projected to reach $15 billion by 2027. This represents a CAGR of 7.5%. - What share of the total skin cancer target market can we estimate is realistic for to obtain? A conservative estimate is that our company should be able to reach $150 million USD in annual revenues by the close of 2028. • Problem or Need: - The main project involves the development of a Skin Cancer Patient Data Blockchain. - Currently there is a serious problem concerning how oncology patients organize and share their medical data, how companies get access to this data, and a lack of return in value to the patients for sharing their personal data. The blockchain is designed to tackle and solve these problems. - The blockchain for skin cancer patients will be comprised of multiple decentralized nodes contributing data to a shared ledger where patients can set up smart contracts to share and control their data. - Skin cancer patients will be able to share their data with research institutions, drug companies, diagnostic companies, contract research organizations, client trials organizers, and other stakeholders. - Also, planning to launch a medium of exchange within the blockchain system to allow patients to be given money for participation in the sharing of their data with the mentioned company stakeholders. - Therefore, the company stakeholders that plan to utilize the patient’s data would provide revenues and income to support the operations of the blockchain. - For example, pharmaceutical companies would be important customers that the business would cultivate as users of the patient’s healthcare data. This is because pharma companies can use this blockchain to discover patients with the right profile for a skin cancer clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. This should greatly streamline for the pharma company the time it takes to enroll the right patients into clinical trials and get them started. • Solution: - What is the core value proposition? For the company stakeholders in the skin cancer patient blockchain, the business is hoping to demonstrate that this blockchain technology will be a way to improve business outcomes through better efficiency, risk management, and security. - For these customers, this will enable them to maintain and capture new sources of profit. At the same time, company stakeholder participation will also grow the business as the integrator and host of the blockchain and result in significant profit growth for the company. • Team: The team is comprised of: - Founder, President, and CEO, a 100% full-time permanent employee has a Ph. D. in Cell and Molecular Biology from St. John’s University (New York, NY), a M. S. in Microbiology & Immunology from Long Island University, and a M. B. A. from Le Moyne College. In addition, he has 20 years of quality assurance and regulatory affairs experience at the Bristol-Myers Squibb Company, Charles Rivers Laboratories, and Vybion, Inc. This includes moving numerous human therapeutic products from R&D, through clinical trials, and into the marketplace via approval by the US FDA and worldwide regulatory bodies. In addition to the above experience, and an addition 18 year of experience in human therapeutics research and development and in the management of laboratory-based cell culture, toxicological, or bioassay projects within the biopharmaceuticals industry. However, he is a Senior Member of the food, drugs & cosmetics section of the American Society for Quality (ASQ), and a society member of The American Association for the Advancement of Science (AAAS). - The President of Hillberg Consulting is a part-time, non-permanent hourly contract employee of R&D department. She is an accomplished executive and board member with a reputation for delivering bottom-line profitability while building the infrastructure to support growth and success. She has served at Johnson & Johnson Ortho Clinical Diagnostics as VP of R&D, and as Chief Technology, Officer at Carestream Health. Holly has a B. S. in Chemical Engineering from Michigan Technology University and a M. S. in Electrical Engineering from Rochester Institute of Technology. - Marketing Consultant - part-time, non-permanent hourly employee. He is a professional engineer and entrepreneurial executive with focus on emerging technology solutions applied to real world problems. He has substantial experience in team building and in developing market strategies & partnerships. This includes over two decades of technology & networks business planning, development, & implementation. He has a Masters in Entrepreneurial Studies - MIT Sloan School of Management, and M. S. & B. S. in Engineering from Syracuse U. and Utica College. - Blockchain Development Technical Project Management Consultant - Part-time, non-permanent hourly employee that is a contractor from EffectiveSoft Corporation, San Diego, CA. She has eight years of experience as VP of Service Delivery and as the Head of Sales for enterprise level software solutions at Effective Soft Corp. She has a M. B. A. from The University of Manchester and a B. S. degree from Minsk State Linguistics U. – Legal Counsel - Part-time, non-permanent hourly contract employee. He holds the Juris Doctor from Boston College Law School, and B. A. in Political Science from Binghamton University. He is a Partner at Newman & Lickstein, with eight years of experience in representing technology companies and investors in licensing, IP development, real estate, mergers & acquisitions, and business litigation. - Demonstrating results to stakeholders will be the key to success. For skin cancer, there is a lot of data collected from various heterogeneous sources – pathology imaging data, genetic testing, surgery, drugs intervention, payer, and insurance information, etc. - Some companies are using a website or app to meet the social needs of patients to discuss their concerns with other patients or a few qualified physicians. No competitor is comprehensively focusing on skin cancer data & treatment to the level that we do. Possible competitors have thus not yet integrated the patient data, shared consent, and the patient monetization blocks together into a comprehensive and workable blockchain system for skin cancer patients, or for any segment of the oncology market, for that matter. - This team, on the other hand, has decades of experience in oncology research, the development of products and services for cancer patients, in oncology clinical biomedicine and in oncology marketing, and that makes the company well-equipped to solve the problems around skin cancer patient data acquisition, its organization, and its beneficial use for the patients and for their healthcare providers. For example, regarding the latter, the company also harnesses artificial intelligence (AI) and machine learning (ML) to extract relevant data from the patient’s database that will help healthcare providers to better understand the patient’s tumor and the tumor microenvironment (i. e. , tumor growth, cellular migration, blood supply to the tumor, subcellular trafficking, and tumor metastasis), drug efficacy (including drug penetration into the tumor, possible tumor shrinkage or tumor death, and drug toxicity, and side effects), or the immediate or long term results of surgical intervention. - When competitors enter this specific market, the business plans to stand out by utilizing a value-based strategy that clearly displays our brand and the above competitive advantage. • Traction: - Currently works with pharmaceutical and diagnostic companies, research institutes, and contract research development and manufacturing companies to help them obtain and organize their molecular bioassays and pathology data. We propose to utilize this traction and intercompany personal connections to gain and grow customers that will use and pay for patient data on the blockchain. - Also use social media & patient advocacy organization to recommend the blockchain to skin cancer patients so that we can grow the patient database. - The company is also a member of the Hyperledger Foundation Healthcare Special Interest Group. Hyperledger, as part of the Linux Foundation, provides technology leaders a uniquely open and collaborative international community from which to develop, validate, and field enterprise-grade blockchain technology solutions. It is the mandate of the Hyperledger Healthcare Special Interest Group (HC-SIG) to represent healthcare professionals and technologists, to globally unite these individuals, and to advance the state of the healthcare industry through the implementation of technology solutions using blockchain technologies in general, and the umbrella of Hyperledger frameworks and toolsets specifically. • Revenue Model: - Within the ecosystem surrounding the above patients, who would buy/lease the skin cancer blockchain services that the company wish to market? In this blockchain system, individuals will be allowed to store and monetize their own health data including blood test results, medical history, genetic profile, skin photographs, pathology images and other sensitive information. - In the healthcare marketplace, cancer patients would be paid in stablecoin currency to lease their individual data to companies for a certain amount of time. - Pharmaceutical (pharma) companies would be important customers that the company would cultivate as users of the patient’s permitted healthcare data. - Blockchain can help pharma companies discover patients with the right profile for a clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. - According to Milind Kamkolkar, chief data officer at Sanofi, patients could be prompted based on their data to join a clinical trial, thereby also accelerating the process and accuracy of trial recruitment. Using this blockchain if a person declines, no personal information will be shared, and the person's identity will remain private. If the person agrees, the overall process will move faster by abolishing the need for intermediaries. - For pharma companies, better inclusion in clinical trials and better reproducibility for studies can reduce the time and money needed to develop new drugs. - Besides pharma companies, research institutes will be willing to pay for the data from skin cancer patients, and the introduction of our blockchain-based data ecosystem may help ensure that the individuals take control over their data and companies and research institutions may acquire data more freely after the latter have obtained consent from individual patients. - How are the products and services going to generate revenue? The most straightforward way to generate revenue is to have the blockchain client customers pay for the products and services that exceeds by a large margin what it costs to develop and operate the blockchain (a cost-plus strategy). - When competitors enter this specific market, plan to stand out by utilizing a value-based strategy that clearly displays the brand and competitive advantage. • Market Projections: - What share of the total skin cancer blockchain target market can we estimate is realistic for to obtain? The global skin cancer blockchain customer market size stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. A conservative estimate is that the company should be able to reach $150 million in annual revenues in 4 years. - These financial projections would be possible because of the company participating and partnering with individuals and companies within the oncology community to create superior value for the products and services. - Over the next 4 years, the company anticipates receiving funding from investors, and revenues from pharmaceutical companies and research institute customers. - However, expenditures are also expected to increase. Expenses incurred will be for the development of products and services, and for personnel, equipment, supplies, business development & marketing. • Competition: - Have identified Nebula Genomics and Longenesis as competition. These two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data. - Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical genetics data. - Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data. - The above companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. To automate data acquisition, the project developed by both Nebula Genomics and Longenesis will utilize smart contracts. - Unlike the Nebula Genomics and Longenesis blockchains, this blockchain project will be focused on oncology patients and the ecosystem around them rather than on a multitude of disease sectors. - In addition to Nebula Genomics and Longenesis, the U. S. -based life science research marketplace, Scientist. com, has revealed the development of a pharmaceuticals blockchain platform. This latter blockchain-powered platform is reportedly designed to track and protect pharmaceutical data. Thus, the Scientist. com DataSmart TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered before submission to regulators such as the FDA and the EMEA. - However, the above platforms do not adequately address the pressing concerns of cancer patients regarding the control and sharing of their personal data. Competitive Advantage: • Strategy. Specifically for oncology blockchain products, the major company players that may join our blockchain to gain access to data from skin cancer patients include: Almirall S. A. Amgen, Inc. Boehringer Ingelheim GmbH. Bristol-Myers Squibb Company. Eli Lilly and Company. Elekta AB. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc. Merck & Co. , Inc. Mylan NV. Novartis AG. Pfizer. Regeneron. Sanofi. Sun Pharmaceutical Industries Ltd. Varian Medical Systems, Inc. Sensus Healthcare. ICAD, Inc. Accuray, Inc.